Hematological toxicities and thrombosis risk associated with immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2024 - PubMed
5 hours ago
- #hematological toxicities
- #immune checkpoint inhibitors
- #pharmacovigilance
- Immune checkpoint inhibitors (ICIs) are linked to hematological toxicities and thrombosis risks, studied via the FAERS database from 2014 to 2024.
- Analysis identified 14,753 ICI-associated events, with a higher reporting frequency in men (50.90%) than women (40.11%).
- The most frequent adverse events were anemia, thrombocytopenia, febrile neutropenia, neutropenia, myelosuppression, pancytopenia, lymphadenopathy, DIC, leukopenia, and DVT.
- Median time-to-onset for ICI monotherapy AEs was 28 days, with 78.22% occurring within 3 months.
- DIC and DVT had the highest mortality proportions among the top 10 adverse events.
- Combination regimens showed stronger reporting signals for certain events, emphasizing the need for clinical vigilance.